Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market Research Report To 2022: Grand View Research, Inc.

Novel Drug Delivery Systems (NDDS) in Cancer Therapy
Competitive Strategies and Forecasts, 2015 to 2022
Growing prevalence of various types of cancer such as carcinoma, sarcoma, etc.
and increasing awareness regarding the drawback of chemotherapy are few factors
which are expected to boost NDDS in cancer therapy market. Additionally,
growing demand for ART for the patients suffering from HIV/AIDS, changing
lifestyles such as high tobacco and alcohol consumption and rising demand for
novel drug delivery systems such as transdermal patches are the high impact
rendering drivers for the growth of this market. Furthermore, rising awareness
among healthcare professionals regarding benefits associated with nanoparticles &
embrolic agents and technological advancement such as incorporation of
nanotechnology in drug delivery system, vaccine drug delivery system & prodrugs
for targeted drug delivery are few factors expected to positively reinforce NDDS in
cancer therapy market over the forecast period.
For More Information on "Novel Drug Delivery Systems (NDDS) in Cancer
On the basis of technologies the market is segmented into liquid embrolic,
nanoparticles and embolization particles. In 2014, Nanoparticles was one of the
highest revenue generating technological segment. Key factors attributing to its
large share include growing demand for protecting the drugs from being damaged
before reaching the specified area, easy diagnosis by the oncologist to observe how
well they are working and preventing the drug interaction with the normal cells or
Nanoparticles used for cancer therapy include DepoCyt (liposomal cytarabine),
Megace ES (megestrol acetate), Abraxane (paclitaxel), Doxil (doxorubicin),
Myocet (doxorubicin) and DaunoXome (daunorubicin citrate). Embolization
particles are further segmented into PVA particles, microspheres, drug eluting beds
(DEB), microspheres, radioembolization microspheres/selective internal radiation
therapy (SIRT). Key regional markets included in the study are North America,
Europe, Asia Pacific, MEA and Latin America. In 2014, North America accounted
for significant market share in terms of revenue owing to the factors such as rising
incidences of cancer, growing awareness regarding upcoming technologies and
treatment options such as target drug delivery, nanoparticles and rising government
investment in this sector. However, Asia pacific region is anticipated to witness
significant growth over the forecast period.
Key factors attributing to its rapid growth include economic development in
countries such as Japan, China, India, New Zealand and Australia, favorable
government initiatives pertaining to the development of healthcare infrastructure
and constantly improving reimbursement policies.
Key players operating in NDDS in cancer therapy market include Advanced
Medical Isotope Corporation, Boston Scientific Corporation, Bind Therapeutics,
Cook Medical Inc., CeloNova BioSciences Inc., BTG plc, Covidien plc, Cospheric
LLC, Merit Medical Systems, Inc., EmboMedics Inc., Eckert & Ziegler BEBIG,
Kobo Products, Inc., Polysciences Inc., Nanobiotix, Mo-Sci Corporation and Sirtex
Medical Limited.
Request TOC of “Novel Drug Delivery Systems (NDDS) in Cancer Therapy
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports,
and consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals, materials,
healthcare and energy.
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Website: Grand View Research
Blog Site: